Dyne Therapeutics (DYN) Competitors $8.28 -0.63 (-7.07%) Closing price 04:00 PM EasternExtended Trading$8.96 +0.68 (+8.20%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DYN vs. AAPG, MRUS, ACLX, SWTX, ACAD, RNA, SRRK, PTGX, VKTX, and MLTXShould you be buying Dyne Therapeutics stock or one of its competitors? The main competitors of Dyne Therapeutics include Ascentage Pharma Group International (AAPG), Merus (MRUS), Arcellx (ACLX), SpringWorks Therapeutics (SWTX), ACADIA Pharmaceuticals (ACAD), Avidity Biosciences (RNA), Scholar Rock (SRRK), Protagonist Therapeutics (PTGX), Viking Therapeutics (VKTX), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry. Dyne Therapeutics vs. Its Competitors Ascentage Pharma Group International Merus Arcellx SpringWorks Therapeutics ACADIA Pharmaceuticals Avidity Biosciences Scholar Rock Protagonist Therapeutics Viking Therapeutics MoonLake Immunotherapeutics Ascentage Pharma Group International (NASDAQ:AAPG) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends. Does the media prefer AAPG or DYN? In the previous week, Ascentage Pharma Group International and Ascentage Pharma Group International both had 12 articles in the media. Ascentage Pharma Group International's average media sentiment score of 0.45 beat Dyne Therapeutics' score of 0.43 indicating that Ascentage Pharma Group International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascentage Pharma Group International 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Dyne Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Is AAPG or DYN more profitable? Ascentage Pharma Group International's return on equity of 0.00% beat Dyne Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Ascentage Pharma Group InternationalN/A N/A N/A Dyne Therapeutics N/A -52.83%-48.84% Do institutionals & insiders have more ownership in AAPG or DYN? 96.7% of Dyne Therapeutics shares are held by institutional investors. 20.8% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has higher valuation & earnings, AAPG or DYN? Ascentage Pharma Group International has higher revenue and earnings than Dyne Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAscentage Pharma Group International$134.35M23.84-$55.54MN/AN/ADyne TherapeuticsN/AN/A-$317.42M-$3.59-2.31 Do analysts rate AAPG or DYN? Dyne Therapeutics has a consensus target price of $40.63, suggesting a potential upside of 390.64%. Given Dyne Therapeutics' higher probable upside, analysts clearly believe Dyne Therapeutics is more favorable than Ascentage Pharma Group International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ascentage Pharma Group International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Dyne Therapeutics 0 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 2 Strong Buy rating(s) 3.00 SummaryAscentage Pharma Group International and Dyne Therapeutics tied by winning 5 of the 10 factors compared between the two stocks. Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DYN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DYN vs. The Competition Export to ExcelMetricDyne TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.01B$2.44B$5.62B$9.30BDividend YieldN/A1.79%4.25%4.03%P/E Ratio-2.319.1428.5719.58Price / SalesN/A676.50424.2194.37Price / CashN/A164.3436.0257.93Price / Book1.344.608.135.54Net Income-$317.42M$30.99M$3.24B$257.73M7 Day Performance-1.31%0.77%2.03%0.95%1 Month Performance-42.54%23.11%8.29%10.68%1 Year Performance-80.90%-5.46%28.40%15.67% Dyne Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DYNDyne Therapeutics4.0105 of 5 stars$8.28-7.1%$40.63+390.6%-78.6%$1.01BN/A-2.31100Analyst ForecastInsider TradeAAPGAscentage Pharma Group InternationalN/A$42.04-1.9%N/AN/A$3.66B$980.65M0.00600News CoverageGap UpMRUSMerus1.9444 of 5 stars$52.58-2.3%$84.64+61.0%-2.9%$3.64B$36.13M-12.8937Analyst UpgradeACLXArcellx2.5417 of 5 stars$65.55-2.4%$111.23+69.7%+12.0%$3.61B$107.94M-21.9280News CoveragePositive NewsSWTXSpringWorks Therapeutics1.5968 of 5 stars$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230ACADACADIA Pharmaceuticals4.5676 of 5 stars$20.88-0.3%$27.88+33.5%+23.2%$3.49B$957.80M15.24510Analyst RevisionRNAAvidity Biosciences2.3209 of 5 stars$28.80-1.3%$65.59+127.7%-25.1%$3.47B$10.90M-9.60190SRRKScholar Rock3.6859 of 5 stars$35.48-1.4%$42.67+20.3%+324.1%$3.37B$33.19M-14.02140PTGXProtagonist Therapeutics1.4563 of 5 stars$49.87-2.3%$66.10+32.5%+52.9%$3.09B$434.43M66.49120Positive NewsVKTXViking Therapeutics4.6081 of 5 stars$27.51-2.4%$87.15+216.8%-44.7%$3.09BN/A-23.9220MLTXMoonLake Immunotherapeutics1.7387 of 5 stars$47.50-2.8%$74.50+56.8%+9.6%$3.04BN/A-20.652News Coverage Related Companies and Tools Related Companies Ascentage Pharma Group International Competitors Merus Competitors Arcellx Competitors SpringWorks Therapeutics Competitors ACADIA Pharmaceuticals Competitors Avidity Biosciences Competitors Scholar Rock Competitors Protagonist Therapeutics Competitors Viking Therapeutics Competitors MoonLake Immunotherapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DYN) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
